Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies

Xu, Shengtao; Wang, Guangyu; Lin, Yi; Zhang, Yanju; Pei, Lingling; Yao, Hong; Mei, Hu; Qiu, Yangyi; Huang, Zhangjian; Zhang, Yihua; Xu, Jinyi

doi:10.1016/j.bmcl.2016.04.068

Cited by 32 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…resulted in tumour inhibitory rates (TIR) of 45.9% and 62.5%, respectively, which was significantly superior to the parent compound palmatine (TIR of 41.6% at a dose of 30 mg/kg). This finding agrees with those that showed NO-donating hybrids possessed greater antitumor activity than sole NO donors, parent drugs and/or their combinations [130][131][132][133][134]. Since NO has a very short half-life, its controlled release through NO donating compounds appear to be a valuable strategy for the synthesis of novel anticancer agents.…”

Section: The Berberine-o-derivativessupporting

confidence: 89%

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Habtemariam

2020

Molecules

View full text Add to dashboard Cite

Berberine is multifunctional natural product with potential to treat diverse pathological conditions. Its broad-spectrum anticancer effect through direct effect on cancer cell growth and metastasis have been established both in vitro and in vivo. The cellular targets that account to the anticancer effect of berberine are incredibly large and range from kinases (protein kinase B (Akt), mitogen activated protein kinases (MAPKs), cell cycle checkpoint kinases, etc.) and transcription factors to genes and protein regulators of cell survival, motility and death. The direct effect of berberine in cancer cells is however relatively weak and occur at moderate concentration range (10–100 µM) in most cancer cells. The poor pharmacokinetics profile resulting from poor absorption, efflux by permeability-glycoprotein (P-gc) and extensive metabolism in intestinal and hepatic cells are other dimensions of berberine’s limitation as anticancer agent. This communication addresses the research efforts during the last two decades that were devoted to enhancing the anticancer potential of berberine. Strategies highlighted include using berberine in combination with other chemotherapeutic agents either to reduce toxic side effects or enhance their anticancer effects; the various novel formulation approaches which by order of magnitude improved the pharmacokinetics of berberine; and semisynthetic approaches that enhanced potency by up to 100-fold.

show abstract

Section: The Berberine-o-derivativessupporting

confidence: 89%

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Habtemariam

2020

Molecules

View full text Add to dashboard Cite

show abstract

“…Dependent on previous studies, researchers synthesized a series of novel NO-releasing oridonin derivatives coupling diazeniumdiolates with oridonin (30). The hybrids inhibited tumor cell proliferation with IC 50 ranging from 1.84 to 17.01 μM.…”

Section: No-oridonin Hybridsmentioning

confidence: 99%

Nitric oxide donor hybrid compounds as promising anticancer agents

Ding

Zang

Gao

et al. 2016

DD&T

View full text Add to dashboard Cite

“…The cause of cardiovascular issues may be due to inhibition of vasodilatory prostacyclin (PGI 2 ) and an increase in the level of platelet activator thromboxane A 2 (TxA 2 ) [11]. Nitric oxide (NO) showed vasodilator activity and inhibition of platelet aggregation [12]. Accordingly, attachment of NO donor moiety to selective COX-2 inhibitors may be beneficial to overcome the cardiovascular side effects [13,14].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl) indole derivatives: multi-target compounds with dual antimicrobial and anti-inflammatory activities

et al. 2020

View full text Add to dashboard Cite

Three series of 2-(4-methylsulfonylphenyl) indole derivatives have been designed and synthesized. The synthesized compounds were assessed for their antimicrobial, COX inhibitory and anti-inflammatory activities. Compound 7g was identified to be the most potent antibacterial candidate against strains of MRSA, E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii, respectively, with safe therapeutic dose. Compounds 7a-k, 8a-c, and 9a-c showed good antiinflammatory activity with excessive selectivity towards COX-2 in comparison with reference drugs indomethacin and celecoxib. Compounds 9a-c were found to release moderate amounts of NO to decrease the side effects associated with selective COX-2 inhibitors. A molecular modeling study for compounds 7b, 7h, and 7i into COX-2 active site was correlated with the results of in vitro COX-2 inhibition assays.

show abstract

Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies

Cited by 32 publications

References 22 publications

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Nitric oxide donor hybrid compounds as promising anticancer agents

Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl) indole derivatives: multi-target compounds with dual antimicrobial and anti-inflammatory activities

Contact Info

Product

Resources

About